Medindia

X

Patheon to feature its capabilities at INTERPHEX JAPAN 2010 convention

Thursday, June 17, 2010 Corporate News J E 4
Advertisement
RESEARCH TRIANGLE PARK, NC, June 16 /PRNewswire-FirstCall/ - Patheon (TSX: PTI) a global provider of drug development and manufacturing services to the international pharmaceutical industry invites customers, potential customers and representatives of the media to visit Patheon's booth number 42-24 in the Pharma Sourcing 2010 area to learn more about the comprehensive service offerings and specialized capabilities it provides to the biopharmaceutical industry.

In 2009, Patheon provided services to approximately 300 customers throughout the world, including 19 of the world's 20 largest pharmaceutical companies, six of the world's 10 largest biotechnology customers and seven of the world's 10 largest specialty pharmaceutical companies. The company manufactured 13 of the 200 top selling drug compounds in the world and its products were distributed in approximately 50 countries. Patheon is currently developing 11 of the top 100 developmental stage drugs in the world on behalf of its customers.

INTERPHEX JAPAN is Asia's largest pharmaceutical industry event with over 1,770 exhibitors that provide insights and inspiration on the major trends in the industry today.

ABOUT PATHEON

Patheon is a leading global provider of contract development and manufacturing services to the global pharmaceutical industry. Patheon prides itself in providing the highest quality products and services to approximately 300 of the world's leading pharmaceutical and biotechnology companies. Patheon's services range from preclinical development through commercial manufacturing of a full array of dosage forms including parenteral, solid, semi-solid and liquid forms. Patheon uses many innovative technologies including single-use disposables, liquid-filled hard capsules and a variety of modified release technologies. Patheon's comprehensive range of fully integrated Pharmaceutical Development Services includes pre-formulation, formulation, analytical development, clinical manufacturing, scale-up and commercialization. Patheon can take customers direct to clinic with global clinical packaging and distribution services and Patheon's Quick to Clinic(TM) programs can accelerate early phase development project to clinical trials while minimizing the consumption of valuable API. Patheon's integrated development and manufacturing network of 11 facilities and eight development centers, across North America and Europe, strives to ensure that customer products can be launched timely and confidently anywhere in the world.

SOURCE Patheon Inc.
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
ThermoGenesis Announces Agreement Related to Plan ...
S
OncoMed Pharmaceuticals and Bayer Schering Pharma ...